US 12,461,113 B2
IGFBP7 ratio for HFpEF
Kai Habben, Mannheim (DE); Vinzent Rolny, Penzberg (DE); Anika Mang, Mannheim (DE); Ursula-Henrike Wienhues-Thelen, Penzberg (DE); and Serge Masson, Rotkreuz (CH)
Assigned to Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Appl. No. 17/613,353
Filed by Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
PCT Filed May 22, 2020, PCT No. PCT/EP2020/064276
§ 371(c)(1), (2) Date Nov. 22, 2021,
PCT Pub. No. WO2020/234451, PCT Pub. Date Nov. 26, 2020.
Claims priority of application No. 19176160 (EP), filed on May 23, 2019.
Prior Publication US 2022/0229075 A1, Jul. 21, 2022
Int. Cl. G01N 33/74 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/74 (2013.01) [G01N 33/6893 (2013.01); G01N 2333/4737 (2013.01); G01N 2333/58 (2013.01); G01N 2333/65 (2013.01); G01N 2800/325 (2013.01); G01N 2800/56 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method for differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in a subject suffering from heart failure, said method comprising the steps of
(a) determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), a BNP-type peptide and CRP (C-reactive protein) in a blood, serum or plasma sample from the subject,
(b) calculating a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of the BNP-type peptide,
(c) comparing the ratio calculated in step (b) with a reference ratio,
(d) differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), and
(e) administering at least one medicament to the subject suffering from heart failure, wherein the at least one medicament is selected from the group consisting of a sodium-glucose cotransporter-2 inhibitor, a soluble guanylate cyclase stimulator, an inorganic nitrate, an angiotensin receptor-neprilysin inhibitor, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta adrenergic blockers, aldosterone antagonists, and diuretics.